Breast Cancer News and Research

Latest Breast Cancer News and Research

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

11 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.

10 Jan 2011

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

9 Jan 2011

Malaria drug makes cancer drug more effective

Scientists investigating the cancer-fighting properties of artesunate - a drug commonly used to treat malaria - have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels.

7 Jan 2011

Hologic announces acquisition of Interlace Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN Surgical Products division.

From Hologic, Inc. 7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Elevated fat and cholesterol levels found in a typical American-style diet play an important role in the growth and spread of breast cancer, say researchers at the Kimmel Cancer Center at Jefferson.

7 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

A current New England Journal of Medicine study indicates that the use of the PARP inhibitor iniparib in combination with standard chemotherapy to treat metastatic triple-negative breast cancer offers a significant increase in clinical benefit, a measure of durable response or disease stabilization, as well as an increase in progression-free survival.

6 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

6 Jan 2011

OpEds: Sebelius, Fla. Attorney General, USA Today, Wash Post opine about repeal strategies

Over the past nine months, I've traveled around the country and seen the benefits of this law firsthand. Unless we want to take coverage away from cancer patients, reduce oversight for insurance companies, raise prescription drug costs for seniors, weaken Medicare, add $1 trillion to the deficit and undo dozens of other reforms that are improving health around the country, we can't afford repeal (Kathleen Sebelius, 1/5).

6 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Revolutions Medical Corporation recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

4 Jan 2011

Speaker Pelosi releases statement on Republican legislation to repeal the Affordable Care Act

Speaker Nancy Pelosi released the following statement today after the incoming House Republican leadership posted their legislation to repeal the Affordable Care Act:

4 Jan 2011

Personality characteristics impact psychological recovery after breast cancer treatment

Certain personality traits are linked to higher quality-of-life scores in breast cancer patients who undergo breast reconstruction after mastectomy, reports a study in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

4 Jan 2011

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

By sticking a chemical group to it at a specific site, a protein arrests an enzyme that may worsen and spread cancer, an international research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the January issue of Nature Cell Biology.

4 Jan 2011

Breast Cancer News and Research

Latest Breast Cancer News and Research

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Malaria drug makes cancer drug more effective

Hologic announces acquisition of Interlace Medical

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

New technique to analyze and quantify changes in protein

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

OpEds: Sebelius, Fla. Attorney General, USA Today, Wash Post opine about repeal strategies

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Single cancer cell could be detected in future using new test

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Speaker Pelosi releases statement on Republican legislation to repeal the Affordable Care Act

Personality characteristics impact psychological recovery after breast cancer treatment

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Breast Cancer News and Research

Latest Breast Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in